Bristol-Myers Squibb Says FDA Schedules Oncologic Drugs Advisory Committee Meeting For September 26 To Discuss PD-L1 Expression Levels In Gastric And Esophageal Cancers
Portfolio Pulse from Benzinga Newsdesk
Bristol-Myers Squibb announced that the FDA has scheduled an Oncologic Drugs Advisory Committee meeting for September 26 to discuss PD-L1 expression levels in gastric and esophageal cancers.
August 22, 2024 | 7:08 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bristol-Myers Squibb will participate in an FDA advisory meeting on September 26 to discuss PD-L1 expression levels in gastric and esophageal cancers, which could impact their oncology drug portfolio.
The FDA meeting could provide insights into regulatory perspectives on PD-L1 expression, potentially affecting BMY's oncology drug development and approval processes. However, the immediate impact on stock price is uncertain until outcomes are known.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90